BTN3A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1444269	0.59	18/20
SCHEMBL443104	0.65	14/20
SCHEMBL2785834	0.56	13/20
SCHEMBL850195	0.50	12/20
SCHEMBL2510990	0.50	12/20
SCHEMBL2510991	0.50	12/20
SCHEMBL2512431	0.50	12/20
SCHEMBL2521572	0.50	12/20
SCHEMBL2521573	0.50	12/20
SCHEMBL2549985	0.50	12/20
SCHEMBL1374978	0.67	11/20
SCHEMBL882001	0.58	11/20
SCHEMBL1444250	0.43	11/20
SCHEMBL570052	0.72	10/20
SCHEMBL524066	0.55	10/20
SCHEMBL524067	0.55	10/20
SCHEMBL800889	0.53	10/20
SCHEMBL784413	0.52	10/20
SCHEMBL807682	0.57	9/20
SCHEMBL790348	0.50	9/20

Clinical trials — most relevant to BTN3A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine	PHASE4	COMPLETED
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache	PHASE3	RECRUITING
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients	PHASE2	COMPLETED
Skin Test Study of BM32	PHASE1/PHASE2	COMPLETED
Alemtuzumab to Treat Sporadic Inclusion Body Myositis	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Safety Study of High Doses of Zinc in ALS Patients	PHASE1/PHASE2	COMPLETED
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING
Variability of the Unique Fiber Potentials of a Spastic Muscle Treated With Botulinum Toxin	nan	COMPLETED
Transcranial Magnetic Stimulation (TMS) Studies of Dystonia	nan	COMPLETED
Assessment of Vitamin D Supplementation and Immune Function	nan	COMPLETED
Biomarkers of Risk of Parkinson Disease	nan	COMPLETED
High-definition Surface Electromyography Markers for the Diagnosis of Sarcopenia	nan	RECRUITING
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development	nan	COMPLETED
Genetic Studies of Inflammatory Bowel Disease	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Non-Motor Features of Cervical Dystonia (CD)	nan	COMPLETED
TL1A Expression in Psoriatic Skin	nan	UNKNOWN
BSCU1 and Immune Function	nan	COMPLETED
High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia	nan	RECRUITING
Critical Illness Weakness Outside the Intensive Care Unit.	nan	RECRUITING
The Etiology and Progression of Brain Tumors	nan	COMPLETED
Nerve Ultrasound in Acquired and Genetic Sensory Neuronopathies	nan	NOT_YET_RECRUITING
Longitudinal Biomarkers With Selected Outcome Measures In CMT	nan	RECRUITING
Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease	nan	UNKNOWN
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy	nan	UNKNOWN
Prognostic Value of Biomarkers in Polyneuropathy.	nan	RECRUITING
Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a BTN3A1 binder may also engage these)

Protein	Name	Similarity
O00478	—	0.994	O00478 →
Q5R996	—	0.987	Q5R996 →
Q5R7W8	—	0.981	Q5R7W8 →
Q7KYR7	—	0.979	Q7KYR7 →
P18892	—	0.978	P18892 →
Q13410	—	0.978	Q13410 →
Q8WVV5	—	0.977	Q8WVV5 →
P78410	—	0.973	P78410 →
A4QPC6	—	0.972	A4QPC6 →
Q8BGE7	—	0.945	Q8BGE7 →
Q5D7J1	—	0.945	Q5D7J1 →
Q9C030	—	0.944	Q9C030 →
Q9BYJ4	—	0.943	Q9BYJ4 →
P11364	—	0.942	P11364 →
Q9UIR0	—	0.942	Q9UIR0 →
Q62556	—	0.940	Q62556 →
Q2YEM9	—	0.939	Q2YEM9 →
Q9C035	—	0.939	Q9C035 →
Q2YEN0	—	0.938	Q2YEN0 →
Q9ESN2	—	0.938	Q9ESN2 →
Q99PQ2	—	0.936	Q99PQ2 →
Q1ACD8	—	0.936	Q1ACD8 →
A0A0E4BZH1	—	0.936	A0A0E4BZH1 →
Q5C8T6	—	0.935	Q5C8T6 →
Q587N6	—	0.935	Q587N6 →
Q5D7I9	—	0.935	Q5D7I9 →
Q5D7I3	—	0.935	Q5D7I3 →
Q5C8T8	—	0.934	Q5C8T8 →
Q3ZEE5	—	0.934	Q3ZEE5 →
B1H278	—	0.933	B1H278 →